The purine nucleoside adenosine (Ado) causes vasodilation in several organs, including the brain and heart, but a transient vasoconstriction in the kidney. [1] [2] [3] The fact that Ado is formed during increased cellular metabolism and causes vasoconstriction in kidney suggests that Ado mediates tubuloglomerular feedback (TGF). [4] [5] [6] [7] The recent observation of a complete loss of TGF in micropuncture studies of A 1 (À/À) mice provides additional proof. 8, 9 Although there is agreement about the general potency of Ado to induce vasoconstriction in the renal resistance vessels, studies are not consistent with regard to the amount of constriction and the dose required. 10 Two investigations of isolated, perfused Af of rabbits and mice demonstrated a concentration-dependent, strong constriction, which was more pronounced in the distal part of Af close to the entrance into the capillary network of the glomerulus. 11, 12 In contrast, other investigators using the juxtamedullary nephron preparation observed small and biphasic responses upon cumulatively increased concentrations of Ado in rats. 13 These conflicting results may be related to the differential expression of A 1 AR in cortical glomerular arterioles compared to juxtamedullary, and to differences in the method of the analysis of arteriolar responses. 10 Some studies point at a synergistic interaction between the vasoconstrictor A 1 AR and angiotensin II (Ang II) type 1 receptors (AT 1 ) in renal vasculature.
14 For instance, isolated, perfused Af from mice lacking A 1 AR (A 1 AR(À/À)) show an attenuated contractile response to Ang II. 15 These studies focused on actions of Ado on A 1 AR. Pilot studies in our laboratory revealed a distinct influence of A 2 AR on the response upon Ado in isolated, perfused Af. We therefore tested the hypothesis of a contribution of several receptors not only on arteriolar tone but also on the Ado-Ang II interaction. We further investigated to which extent Ang II influences the response of Af upon Ado.
closing of the lumen in all arterioles. Ado caused modest but significant changes of luminal diameter. The response was biphasic ( Figure 1 ). Ado reduced the diameter to 92.571.6% of the control value at 10 À10 mol/l. This constriction waned at higher Ado concentrations (103.272.0% at 10 À4 mol/l; Figure 1 ). A dilation of arterioles was not limited by methodical reasons, that is, the arterioles had a further dilatory capacity, which was shown by the application of the NO donor spermine NONOate (dilation to 111% of the control; Figure 2 ). Treatment with Ang II led to a dose-dependent constriction upon Ado (Figure 1) .
The A 1 AR agonist N 6 -cyclopentyladenosine (CPA) reduced the luminal diameter in dependency on concentration down to 87.973.5% (Figure 3 ). Cumulative application of the A 2A AR-selective agonist CGS21680 produced a dilation up to 113.071.6% (Figure 3 ). The blockade of the vasoconstriction of Ado with the A 1 AR-selective antagonist 8-cyclopentyltheophylline (CPT) provides further evidence that the vasoconstriction is mediated by A 1 AR (Figure 4) . Similarly, in mice lacking the A 1 AR, dilation was uniformly the response ( Figure 5 ). Pretreatment with ZM241385 and MRS1706 or ZM241385 alone caused similar monophasic constrictory responses upon Ado (Figures 6 and 7) , which differed from pure Ado application. CPT and ZM241385 together did not change the Ado response ( Figure 8 ). Pretreatment with 8-SPT (unspecific AR antagonist) neither changed arteriolar tone nor the Ado response ( Figure 8 ).
In A 1 (À/À) mice, the vessels dilated in dependency on concentration upon Ado ( Figure 5 ). The Ado concentration-response curve of A 1 ( þ / þ ) differed significantly from A 1 (À/À) and corresponded to that of the C57BL6 wild-type mice. With regard to the absolute diameters (mm), Af of A 1 (À/À) mice showed a strong tendency toward smaller diameters in the control situation (not significant). There were no differences in age, body mass, or gender distribution between A 1 (À/À) and A 1 ( þ / þ ) mice (not shown).
Cumulative application of inosine did not change luminal diameter of Af from C57BL6 mice ( Figure 9 ). Ado receptor subtypes showed differential expression in isolated preglomerular vessels. The expression was as follows: A 1 AR4 A 2B AR4A 2A AR4A 3 AR ( Figure 10 ).
Cumulative application of Ang II resulted in a concentration-dependent contractile response (Figures 11 and 12 ). Ado treatment in a concentration of 10 À8 mol/l increased the Ang II response significantly ( Figure 11 ). This was prevented by CPT. Treatment with Ado in a concentration of 10 À5 mol/l did not change the Ang II response in Af ( Figure 12 ). Combined treatment with ZM241385 and MRS1706 mimicked the effect of low concentrated Ado. The control diameters of Af did not differ between these series.
DISCUSSION
This study shows an impressive change of the Ado response from a modest and biphasic course into a concentrationdependent constriction of Af when Ang II is present in the solution. Furthermore, it demonstrates that low concentrations of Ado (10 À8 mol/l) amplify the Ang II-induced constriction of the Af. Higher concentrations of Ado (10 À5 mol/l) did not change the response of Af to Ang II. Latter effects are mediated by AR and may reflect the different affinity to A 1 AR and A 2B AR. It is assumed that the increase of the Ang II response by lower Ado concentration is owing to the synergistic action of AT 1 and A 1 AR on phospholipase C. 16 We show that the activation of A 2B AR at higher Ado concentration interfere with this behavior.
Ado-Ang II interactions have been observed at the organ level and in isolated, perfused arterioles before. For example, only combined administration of Ado and Ang II induce vasoconstriction in kidneys of dogs, although these drugs alone do not significantly influence vascular resistance. 1 Also, the Ang II-induced constriction in Af of rabbits was enhanced by Ado in excess of an additive effect. 14 The idea of an interaction between Ado and the Ang II system is supported by results of a recent study showing a reduced response of Af from mice lacking A 1 AR upon Ang II. 15 Conversely, the constrictor action of A 1 AR seems to depend on AT 1A receptors. 17 Deletion of AT 1A receptors or angiotensin-converting enzyme attenuates TGF responses in knockout mice. 17, 18 Altogether, these studies indicate synergistic interactions of Ado and Ang II, which are important for renal blood flow control and TGF. The results of the present study extend this view of Ado-Ang II interaction in Af. The influence of Ado on the Ang II-induced contraction is modulated by A 1 AR and A 2B AR, whose differential activation depends on the Ado concentration. Additionally, the study demonstrates qualitative differences in the response of Af to Ado, that is, a powerful increase of the constriction in the presence of Ang II. This effect may be of importance in the mediation of TGF by Ado.
A 1 AR and probably both A 2A AR and A 2B AR are involved in the control of afferent arteriolar tone in the present study. A 1 AR-mediated actions were demonstrated by the application of CPA, which decreased luminal diameter, and by CPT, which prevented the contractile response. The results of experiments in A 1 (À/À) mice support the conclusions that A 1 AR mediate constriction and that activation of A 2 AR leads to dilation.
A differential effect of A 2A AR and A 2B AR can be estimated considering the different affinity constants of A 2A AR (about 10 À8 mol/l) and A 2B AR (about 10 À5 mol/l) for Ado. 19 Hence, the observed fading of constriction of Af at high Ado concen- trations may be attributed to an occupation of A 2B AR. Further, the missing effect of treatment with high concentrations of Ado on the Ang II-induced constriction suggests the action of low-affinity A 2B AR. Interestingly, A 2A AR inhibition with ZM241385 did not differ from combined A 2A AR and A 2B AR blockade with ZM241385 and MRS1706. This observation would hint at a predominant role of A 2A AR even at higher Ado concentrations. However, a competitive action of ZM241385 on A 2B AR was described for concentrations as used in the present study, which completely inhibit A 2A AR. 20 Therefore, an attenuation of A 2B AR-mediated effects cannot be excluded. Arteriolar dilation upon the A 2A AR agonist CGS21680 supports the idea of a significant A 2A AR function. Notably, the treatment with ZM241385 did not enhance the constrictory response upon Ado in the low-dose range, which was expected assuming a balanced action of A 1 AR and A 2A AR at low Ado concentrations. In summary, the study provides evidence for the role of both A 2A AR and A 2B AR in the control of arteriolar tone. An exact functional characterization of the subtypes is limited by the pharmacological means.
Our results regarding A 2 AR function are in agreement with Tang et al. 21 and Nishiyama et al. 13 They described afferent arteriolar dilation at submicromolar Ado concentrations, which were probably mediated by high-affinity A 2A AR. Tang et al. 21 also suggested activation of low-affinity A 2B AR by Ado concentrations higher than 10 À5 mol/l. The real-time polymerase chain reaction (PCR) of Ado receptor mRNA in isolated preglomerular vessels (interlobular arteries and Af) of C57BL6 showed expression for all AR subtypes. The strongest mRNA expression was observed for A 1 AR and A 2B AR, which exceeded that of A 2A AR. This observation agrees with functional results from the present study, which show that A 2A AR and A 2B AR exert a considerable dilatory action in Af of mice. The A 3 AR expression was very low in the isolated vessels. This observation, and the fact that the A 3 AR agonist inosine did not change arteriolar tone, points to a negligible function of A 3 AR in the control of Af under physiological conditions. Interestingly, the constrictor effect of A 1 AR was enhanced in the presence of Ang II (10 À10 mol/l). This strong modification of the Ado response of Af by Ang II is more than an additive effect. These data contribute to the explanation of an attenuated TGF response in mice with deletion of AT 1A receptors or angiotensin-converting enzyme. The results of the present study partly disagree with results of Ado effects in isolated, perfused Af of rabbits and mice, 11, 12 where maximum reductions of luminal diameters to about 45% 11 and 30% 12 were seen. Af constricted much stronger in the part close to the entrance into the glomerular capillary network. The authors postulated a non-homogeneous distribution of AR in Af with higher or sole expression of A 1 AR at the very distal end. We did not see a pronounced constriction at the distal site when applying Ado or A 1 AR agonists. We can only speculate about reasons for the differences in the Ado responses between the present study and studies mentioned above. These include different perfusion pressures and differences in preparation. For example, in our preparations, the part of the distal tubule adjacent to the glomerulus (macula densa) was always preserved. This may reduce the variability of Af responses as macula densa cells release vasoactive substances that influence afferent arteriolar tone. In how far preservation and partial preservation of macula densa cells, respectively, affect the measurements in this model has not been investigated yet. In conclusion, the present work shows the expression of A 1 AR as well as A 2A AR and A 2B AR in Af and their physiological role in the control of afferent arteriolar tone. The response of Af upon Ado results from the action of constrictor A 1 AR and dilatory A 2 AR, whose balance is shifted in favor of A 1 AR at lower, and A 2 AR at higher Ado concentration. Remarkably, Ang II clearly augments the contractile response of Af to Ado. This points at a close collaboration of both substances in mediating the TGF: at physiological concentrations of Ang II, increased tubular load induces the formation of ATP, which is released from macula densa cells into the extracellular space. There, Ado is formed and strongly sensitizes the contractile response of Af. Furthermore, the data suggest a concentration-dependent action of Ado on the Ang II sensitivity, which works via differential activation of A 1 AR and A 2 AR. The potentiation of the Ang II-induced constriction at low Ado concentrations also may play a role in the TGF.
MATERIALS AND METHODS Animals
Mice of the C57BL6 strain (male, body mass between 20 and 32 g, Scanbur BK AB, Sollentuna, Sweden) were used for the investigation of Ado receptor function in Af. Additionally, Ado A 1 AR receptordeficient mice (A 1 (À/À)) as well as their controls (A 1 ( þ / þ ), female, body mass between 23 and 29 g) were included to test the effect of chronic lack of the A 1 AR receptor. A 1 (À/À) were generated as described by Johansson et al. 22 A 1 (À/À) and A 1 ( þ / þ ) were siblings from mating between A 1 ( þ /À) mice. Animals were fed with standard mouse chow and allowed free access to tap water. All procedures conformed to the Guide for Care and Use of Laboratory Animals prepared by Institute for Laboratory Animal Research. The local ethics committee for Uppsala University approved the procedures for this study.
Dissection and perfusion
Dissection and perfusion procedures have been described before. 23 In brief, outer cortical Af of mice were dissected at 41C in albuminenriched Dulbecco's modified Eagle's medium (0.1%). Arterioles were perfused in a thermo-regulated chamber (371C) fixed on the stage attached to an inverted microscope (Nikon, Badhoevedorp, The Netherlands) using a perfusion system, which allows the adjustment of outer holding and inner perfusion pipettes (Vestavia Scientific, Vestavia Hills, AL, USA). The perfusion pipette, with a diameter of the tip of exact 5 mm, was connected to a reservoir containing the perfusion solution. The pressure in the pressure head was 100 mmHg, which corresponds to physiological pressure and flow (about 50 nl/min) in the connected Af. 23 The criteria for using an arteriole were a good, remaining basal tone and no pronounced vasodilatation. Both criteria were tested by increasing the perfusion pressure fast and assessing the change in the luminal diameter, which corresponds to transient constriction. A further criterion was a fast and complete constriction in response to KCl (100 mmol/l) solution.
Measurement of isotonic contraction
The experiments were recorded by a video system, off-line digitized, and analyzed as described before. 23 In all series, the last 10 s of the 2 min control or treatment period was used for statistical analysis of steady-state responses.
Arterioles were used only in one protocol, which could include a concentration-response curve with or without pretreatment. There were no experiments included in which substances were washed out or applied two times. This design is based on our observation of sustained effects of agonists even when the control diameter was reestablished after the washout.
Solutions
Dulbecco's modified Eagle's medium/F12 with 10 mmol/l HEPES (Invitrogen AB, Lidingö, Sweden) was used for dissection, bath, and perfusion. The pH was adjusted to 7.4 after the addition of bovine serum albumin. The concentration of bovine serum albumin was 0.1% in dissection and bath solutions, and 1% in the perfusion solution. Bovine serum albumin was obtained from SERVA Electrophoresis (Heidelberg, Germany) and Dulbecco's modified Eagle's medium from Sigma-Aldrich (Munich, Germany). The K þ solution had the following composition: NaCl 20, KCl 95, NaHCO 3 25, K 2 HPO 4 2.5, CaCl 2 1.3, MgSO 4 1.2, glucose 5.5 (mmol/l), and was equilibrated with 5% CO 2 in air.
Isolation of preglomerular vessels for receptor expression analysis Afferent arterioles of mice were isolated using a modified iron oxide-sieving technique according to Chaudhari and Kirschenbaum. 24 Basic modification consisted in the perfusion of the kidneys, which was performed via cannulation of the aorta, and the use of smaller sizes for the needles used for separation of the tissue, as well as of smaller pores of the sieves (100 and 80 mm). The isolated vessels were transferred to a tube with 1000 ml trizol and immediately stored at À801C.
Quantitative real-time PCR RNA was isolated using Trizol reagent and reverse transcribed using Superscript and random hexamers (Invitrogen). Quantitative PCR analysis was performed using a GeneAmp 5700 (Applied Biosystems, Darmstadt, Germany). SYBR Green was used for the fluorescent detection of DNA generated during the PCR. The PCR reaction was performed in a total volume of 25 ml with 0.4 pmol/ml of each primer, and 2 Â SYBR Green master mix (Applied Biosystems, Darmstadt, Germany); 2 ml cDNA corresponding to 10 ng RNA was used as template. Primers, which bridge at least one intron, were designed for PCR amplification on the basis of published sequences for mouse: ADORA 1 (NM_009629), ADORA 2a (NM_009630), ADORA 2b (NM_007413), and ADORA 3 (NM_009631). The expression levels of Ado receptor mRNA were analyzed according to the standard curve method and normalized to b-actin.
Determination the standard curve for quantitative real-time PCR 25 PCR reactions for Adora1, 2a, 2b, 3, and b-actin were performed on a Biometra T1 thermocycler using the real-time PCR primers. Each PCR product was cloned into pCR &
II-TOPO
& vector using the TOPO TA Cloning & Kit (Invitrogen, Karlsruhe, Germany) according to the manufacturer's protocol. Positive clones were identified by PCR using vector-and insert-specific primers and grown overnight in a 5 ml LB culture. Plasmids were isolated using QIAprep s columns (Qiagen, Hilden, Germany) according to the manufacturer's protocol. Quantification of DNA was performed on a Beckman DU-600 UV spectrometer at OD260 nm. For standard curve acquisition, four serial factor 0.5 dilutions of plasmid DNA were prepared serving as DNA templates for real-time PCR. Realtime PCR using SYBR Green technology (Applied Biosystems, Darmstadt, Germany) with the above-mentioned primers was carried out amplifying cloned sequence in triplicate for each respective concentration. Subsequently, a melting curve program was applied with continuous fluorescence measurement to check the quality of the PCR product. Linear regression was applied to determine the relationship between logarithm of concentration and c t values and to obtain the coefficients for the transfer function.
Pharmacological agents
The following drugs were used: Ang II, Ado, inosine (A 3 AR agonist), CPA (selective A 1 AR agonist), 2-p-(2-carboxyethyl)phenethylamino- 
Statistics
Analysis of variance (ANOVA) for repeated measurements (nonparametric Brunner test) was used to test concentration-and timedependent changes in the arteriolar diameter (one-way ANOVA) and to check for differences between the groups (two-way ANOVA, SAS system s , SAS Institute, Cary, NC, USA). One-way ANOVA was combined with the Tuckey post hoc test (modified t-test for paired comparisons). Differences between groups were tested using the Kruskal-Wallis-and Mann-Whitney test. The Wilcoxon test was applied for the comparison of treatment effect on control diameter. Data are presented as mean7s.e.m., unless otherwise noted. The confidence level P was set to 0.05 for all statistical tests.
Protocols
The concentration-response curve for Ado was obtained by cumulative application to the bath solution (10 À11 -10 À4 mol/l). To test the dilatory capacity of the vessels, the NO donor spermine NONOate was applied as a bolus (5 Â 10 À4 mol/l) and the vessel's diameters were measured for following 15 min. For investigation of A 1 AR-mediated effects on Af, the concentration-response curve of CPA (selective A 1 AR agonist, 10 À11 -10 À6 mol/l) was measured. Further, the Ado concentration-response curves for A 1 (À/À) mice and their wild-type controls (A 1 ( þ / þ )) were generated. Functional characterization of Ado receptors was also carried out by treatment with CPT (selective A 1 
